🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Denmark / NCT05553652
Recruiting Not applicable

The Effect of ASTARTE™ on Recurrent Urinary Tract Infection

NCT05553652 · tracked via the Priya Life Science Denmark tracker
Phase
Not applicable
Started
2022-09-19
Last updated
2022-09-23

Condition(s) studied

Recurrent Urinary Tract Infection

Investigational drug(s) / intervention(s)

ASTARTE™ oral capsulesPlacebo oral capsules

ASTARTE™ oral capsules: 1 Capsule daily for 6 months

Placebo oral capsules: 1 Capsule daily for 6 months

Study summary

Investigate the effect of dietary supplements/probiotic ASTARTE™ ( L. crispatus, L. rhamnosus, L. jensenii, L. gasseri) on the microbiome composition in the intestine and vagina and thereby a reduction of risk factors for the development of rUTI during 6 months of intervention in women aged 18-40 years. This is measured by the incidence of symptomatic UTI.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
40 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Women 18-40 years of age * Recurrent UTI (2 times UTI within 6 months or \> 3 times UTI infection within one year). * The subjects should be informed about the trial protocol. * The subject must be able to follow the protocol, have provided voluntary consent and have signed the declaration of consent. Exclusion Criteria: * Pregnancy or planning pregnancy * Breastfeeding * Participation in another trial with probiotic the last 30 days. * Hypersensitivity to any ingredient in the study product * Patients primarily admitted for a disorder other than UTI * Antibiotic treatment for any other condition than UTI at time of recruitment the last 30 days

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Gastrounit, Copenhagen University Hospital Hvidovre Hvidovre Copenhagen Recruiting

More Hvidovre University Hospital trials in Denmark

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05553652 on ClinicalTrials.gov ↗ ← All trials in Denmark